The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

por Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R., Caponigro, Giordano
Publicado 2018

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

por Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R., Caponigro, Giordano
Publicado 2020

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

por Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei, Greenberg, Max, Williams, August, Kattermann, Krystina, Damon, Leah, Sovath, Sosathya, Rakiec, Daniel P., Korn, Joshua M., Ruddy, David A., Benes, Cyril H., Hammerman, Peter S., Piotrowska, Zofia, Sequist, Lecia V., Niederst, Matthew J., Barretina, Jordi, Engelman, Jeffrey A., Hata, Aaron N.
Publicado 2019